Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Interest & Investment Income: 2017-2025

Historic Interest & Investment Income for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $1.0 million.

  • Puma Biotechnology's Interest & Investment Income fell 18.56% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 2.61%. This contributed to the annual value of $4.7 million for FY2024, which is 81.34% up from last year.
  • As of Q3 2025, Puma Biotechnology's Interest & Investment Income stood at $1.0 million, which was up 9.21% from $956,000 recorded in Q2 2025.
  • Puma Biotechnology's Interest & Investment Income's 5-year high stood at $1.3 million during Q3 2024, with a 5-year trough of $13,000 in Q1 2021.
  • In the last 3 years, Puma Biotechnology's Interest & Investment Income had a median value of $972,000 in 2024 and averaged $948,182.
  • In the last 5 years, Puma Biotechnology's Interest & Investment Income slumped by 96.63% in 2021 and then soared by 4,030.77% in 2023.
  • Over the past 5 years, Puma Biotechnology's Interest & Investment Income (Quarterly) stood at $13,000 in 2021, then soared by 3,892.31% to $519,000 in 2022, then spiked by 38.54% to $719,000 in 2023, then surged by 70.51% to $1.2 million in 2024, then declined by 18.56% to $1.0 million in 2025.
  • Its Interest & Investment Income stands at $1.0 million for Q3 2025, versus $956,000 for Q2 2025 and $1.1 million for Q1 2025.